Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Proleukin

(Aldesleukin)

Phase 3Protein / enzyme

IIovance Biotherapeutics, Inc.

Aldesleukin is used to treat advanced kidney cancer and melanoma (a type of skin cancer) by helping the immune system fight cancer cells.[1] Proleukin is currently being investigated across 97 indications[3], with its most advanced program in Phase 3.[1]

Proleukin is one of 1765 small molecule programs targeting Glioma. It is currently in Phase 3.

97

Indications

321

Total Trials

16

Active Trials

1,764

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

AIDSActive, not recruiting

Relapsing PolychondritisActive, not recruiting

HIV InfectionActive, not recruiting

Systemic Lupus ErythematosusActive, not recruiting

Polymyalgia RheumaticaActive, not recruiting

Non-Hodgkins LymphomaActive, not recruiting

Merkel Cell Skin CancerActive, not recruiting

Clear Cell Renal CarcinomaActive, not recruiting

CryoglobulinemiaActive, not recruiting

GliomaPhase 2

Active, not recruiting

AIDSPhase 1

Active, not recruiting

Relapsing PolychondritisPhase 2

Active, not recruiting

HIV InfectionPhase 3

Active, not recruiting

Systemic Lupus ErythematosusPhase 3

Active, not recruiting

Polymyalgia RheumaticaPhase 2

Active, not recruiting

Non-Hodgkins LymphomaPhase 2

Active, not recruiting

Merkel Cell Skin CancerPhase 1

Active, not recruiting

Clear Cell Renal CarcinomaPhase 2

Active, not recruiting

CryoglobulinemiaPhase 1

Active, not recruiting

Showing 10 of 97 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Proleukin

IIovance Biotherapeutics, Inc.

Blenoxane

Bristol-Myers Squibb

MS Contin

HHikma Pharmaceuticals LLC

Sporanox

SSebela Pharmaceuticals Development LLC

Fentanyl Citrate

IINSYS Therapeutics Inc

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Ibrance

Aromasin

Silvadene

RRosalind Franklin University of Medicine and Science

Naderin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Metastatic

NCT06236425

Phase 3Recruiting

Neuroblastoma

NCT01704716

Q4 2026

Phase 1/2Recruiting

Induction Therapy

NCT05639972

Q1 2027

Phase 1/2Active, not recruiting

Kidney Cancer

NCT01038778

Q3 2027

Phase 1/2Recruiting

Cancer

NCT07063875

Clinical

Trials by Indication[1]

Metastatic Melanoma37 trials

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019721

Gene Therapy in Treating Patients With Metastatic Melanoma

Completed·UUniversity of Colorado, Denver·Phase 1·NCT00005943

Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00091104·136 enrolled

Show 34 more trials

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02621021·170 enrolled

Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00002669·90 enrolled

Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT02111863·6 enrolled

Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma

Completed·UUniversity of Nebraska··NCT00617799·15 enrolled

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00509288·24 enrolled

Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed·—·Phase 2·NCT00085423·20 enrolled

Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00096382·34 enrolled

Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00058279

Biological Therapy in Treating Patients With Metastatic Melanoma

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00045149

Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019383

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019994

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00303836·58 enrolled

Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00054535

CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02027935·16 enrolled

Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01807182·11 enrolled

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00019175

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01319565·102 enrolled

Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01369875·2 enrolled

Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00003027·482 enrolled

Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1/2·NCT00062036·33 enrolled

Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00085462·61 enrolled

Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00304460·138 enrolled

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00022438

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01993719·33 enrolled

Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01740557·10 enrolled

Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT00924001·1 enrolled

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00019682·185 enrolled

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019669

Interleukin-2 in Treating Patients With Metastatic Melanoma

Unknown status·—·Phase 2·NCT00002845·20 enrolled

Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal

Completed·—·Phase 1/2·NCT00003229

In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma

Withdrawn·NNational Cancer Institute (NCI)·Phase 1·NCT02489266

Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00871481·10 enrolled

Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00072085

Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed·UUniversity of Illinois at Chicago·Phase 2·NCT00003568

Melanoma13 trials

Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma

Completed·SSt. Luke's Medical Center·Phase 2·NCT00002535

Vemurafenib and White Blood Cell Therapy for Advanced Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01585415·12 enrolled

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00726739·21 enrolled

Show 10 more trials

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Unknown status· Sanofi logo

Sanofi·Phase 1/2·NCT00004025·36 enrolled

Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00004022

Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma

Completed·FFred Hutchinson Cancer Research Center/University of Washington Cancer Consortium·Phase 1·NCT00438984·11 enrolled

Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00553306·10 enrolled

Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00612222·4 enrolled

Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00002882·140 enrolled

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Completed·UUniversity of Virginia·Phase 2·NCT00003222·40 enrolled

Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00665470·10 enrolled

Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT01955460·34 enrolled

Vaccine Therapy in Treating Patients With Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00020358

Kidney Cancer12 trials

Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer

Unknown status·HHope Cancer Institute, Inc.·Phase 2·NCT00003181·35 enrolled

Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Metastatic Kidney Cancer

Unknown status·TThe Christie NHS Foundation Trust·Phase 2·NCT00005038

Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Unknown status·—·Phase 2·NCT00002847·14 enrolled

Show 9 more trials

Biological Therapy Plus Chemotherapy in Treating Patients With Metastatic or Recurrent Kidney Cancer

Completed·UUniversity of New Mexico·Phase 1/2·NCT00003585·35 enrolled

Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00018941

Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer

Terminated·UUniversity of Washington·Phase 1·NCT03260504·6 enrolled

High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma

Completed·HHoag Memorial Hospital Presbyterian·Phase 2·NCT00003091·40 enrolled

Adoptive Immunotherapy, Aldesleukin, and Zoledronate in Treating Patients With Stage IV Kidney Cancer and Lung Metastases

Completed·—·Phase 1/2·NCT00588913·20 enrolled

Interleukin-2 and Interferon in Treating Patients With Metastatic Kidney Cancer

Completed·CCentre Leon Berard·Phase 3·NCT00416871·220 enrolled

Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Completed·—·Phase 4·NCT00006864

Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT01038778·47 enrolled

Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer

Completed·CCentre Leon Berard·Phase 3·NCT00416429·456 enrolled

Metastatic Cancer11 trials

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT01583686·15 enrolled

Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer

Terminated·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00704938·3 enrolled

MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT01273181·9 enrolled

Show 8 more trials

CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT01218867·24 enrolled

Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

No longer available·NNational Institutes of Health Clinical Center (CC)··NCT04135092

Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00923806·3 enrolled

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT06253520·210 enrolled

Vaccine Therapy in Treating Patients With Metastatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00021164

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Recruiting·AAulos Bioscience, Inc.·Phase 1/2·NCT05267626·159 enrolled

Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00393029·12 enrolled

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT02111850·21 enrolled

Neuroblastoma7 trials

High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

Recruiting·SSt. Anna Kinderkrebsforschung·Phase 3·NCT01704716·3,300 enrolled

Vaccine Therapy and Interleukin-2 in Treating Young Patients With Relapsed or Refractory Ewing's Sarcoma or Neuroblastoma

Unknown status·MMilton S. Hershey Medical Center·Phase 1·NCT00101309·10 enrolled

Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00054405·40 enrolled

Show 4 more trials

Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00006480

Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00005576·6 enrolled

Interleukin-2 in Treating Children With Stage IV Neuroblastoma Who Have Received Induction Therapy and Peripheral Stem Cell Transplantation

Unknown status·SSt. Anna Kinderkrebsforschung·Phase 2·NCT00003743·25 enrolled

ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

Completed· United Therapeutics logo

United Therapeutics·Phase 1/2·NCT01592045·28 enrolled

76 more indications

Acute Myeloid Leukemia7 trials

Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00274846·21 enrolled

Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia

Completed·MMaxim Pharmaceuticals·Phase 3·NCT00003991·360 enrolled

Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00006363·720 enrolled

Show 4 more trials

High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

Completed·RRoswell Park Cancer Institute·Phase 3·NCT00002945·61 enrolled

Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·SSumithira Vasu·Phase 1·NCT02316964·8 enrolled

Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia

Terminated·FFred Hutchinson Cancer Center·Phase 1/2·NCT02770820·9 enrolled

Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00004128·2,000 enrolled

Interleukin6 trials

A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001005·30 enrolled

Interleukin-2 and Stem Cell Factor in Treating Patients With AIDS or AIDS-Related Cancer

Completed·RRoswell Park Cancer Institute·Phase 1·NCT00058045·1 enrolled

Subcutaneously Administered Aldesleukin ( Interleukin-2; IL-2 ) Therapy in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000821·78 enrolled

Show 3 more trials

Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000948·72 enrolled

Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors

Completed·GGeorgetown University·Phase 2·NCT00003125·24 enrolled

Effect of Interleukin-2 on HIV Treatment Interruption

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00015704·80 enrolled

Lymphoma6 trials

Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma

Completed·UUniversity of Rochester·Phase 1/2·NCT00003356·58 enrolled

Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma

Unknown status·MMilton S. Hershey Medical Center·Phase 1·NCT00006100

Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00059904

Show 3 more trials

Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00002649·206 enrolled

Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00012207·12 enrolled

Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma

Completed·—·Phase 1·NCT00182650·5 enrolled

Non-Small Cell Lung Cancer5 trials

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02133196·85 enrolled

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

Terminated·FFred Hutchinson Cancer Center·Phase 1/2·NCT02408016·11 enrolled

Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer

Recruiting·EEmory University·Phase 1·NCT05493566·15 enrolled

Show 2 more trials

Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer

Terminated·RRoger Williams Medical Center·Phase 1·NCT00569296·5 enrolled

Biological Therapy in Previously Treated Patients With Non-small Cell Lung Cancer

Unknown status·CCancer Biotherapy Research Group·Phase 2·NCT00003090·30 enrolled

Breast Cancer4 trials

Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00005993

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00003199·50 enrolled

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer

Withdrawn·RRoger Williams Medical Center·Phase 1/2·NCT00022230

Show 1 more trial

Biological Therapy in Treating Women With Metastatic Breast Cancer

Unknown status·SSt. Luke's Medical Center·Phase 1/2·NCT00002780·60 enrolled

Mycosis Fungoides3 trials

Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT00052377·46 enrolled

Interleukin-2 in Treating Patients With Mycosis Fungoides

Completed·UUniversity of Washington·Phase 1·NCT00002687·30 enrolled

Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome

Terminated·NNorthwestern University·Phase 2·NCT00005788

Ovarian Cancer3 trials

A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.

Not yet recruiting·UUniversity of Chicago·Phase 1/2·NCT07389239·24 enrolled

Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00652899·14 enrolled

T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT03318900·5 enrolled

Renal Cancer2 trials

Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer

Completed·NNorthwestern University·Phase 1·NCT00278369·20 enrolled

Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00923390·5 enrolled

HIV2 trials

A Study to Evaluate the Effects of Giving IL-2 Alone to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3 Who Do Not Wish to Receive Anti-HIV Therapy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000909·36 enrolled

A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000949·460 enrolled

Immunotherapy2 trials

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01967823·11 enrolled

Low Dose IL2 Immunotherapy in AD

Completed·TThe Methodist Hospital Research Institute·Phase 1·NCT05821153·8 enrolled

TED2 trials

Drosophila-generated CTL

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01271907·3 enrolled

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT03745326·5 enrolled

Effectiveness2 trials

Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00006291·100 enrolled

Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001131·42 enrolled

Leukemia2 trials

Interleukin-2 in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00003148·86 enrolled

Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00005802

Metastatic2 trials

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT06236425·7 enrolled

Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00784524·14 enrolled

HIV infection2 trials

A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000870·200 enrolled

A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00006154·165 enrolled

Acute Lymphoblastic Leukemia2 trials

Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00107354

Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00052520·37 enrolled

Bone Marrow Transplantation2 trials

Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00003962

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00002798·880 enrolled

Stem Cell Transplant2 trials

Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00248430·20 enrolled

Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00303667·50 enrolled

HIV-1 infection2 trials

A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000820·104 enrolled

Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000875·16 enrolled

Type 1 Diabetes2 trials

Adaptive Study of IL-2 Dose Frequency on Regulatory T Cells in Type 1 Diabetes

Completed·—·Phase 1/2·NCT02265809·41 enrolled

Dose-effect Relationship of Low-dose IL-2 in Type 1 Diabetes

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 1/2·NCT01353833·25 enrolled

Drug Therapy2 trials

Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000923·110 enrolled

Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug Therapy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00038259·21 enrolled

Prostate Cancer2 trials

Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00020254

Biological Therapy in Treating Patients With Prostate Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00002637·25 enrolled

Hematologic Cancer2 trials

Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00003243

Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00010192·30 enrolled

Cancer2 trials

Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer

Terminated·CCancer Research UK·Phase 1·NCT01212887·14 enrolled

Adding IL-2 to Tebentafusp to Eradicate Cancer Progression

Recruiting·SSt Vincent's Hospital, Sydney·Phase 1/2·NCT07063875·8 enrolled

Chronic Lymphocytic Leukemia1 trial

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00625729·6 enrolled

Biological Therapy1 trial

Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019084

Glioblastoma Multiforme1 trial

Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma Multiforme

Completed·HHoag Memorial Hospital Presbyterian·Phase 2·NCT00331526·83 enrolled

Colorectal Cancer1 trial

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

Withdrawn·—·Phase 1·NCT06626256

Radiation Therapy1 trial

Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx

Unknown status·EEuropean Institute of Oncology·Phase 3·NCT00002702·260 enrolled

Gene Therapy1 trial

Non-Viral TCR Gene Therapy

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT04102436

Renal Cell Carcinoma1 trial

Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma

Completed· Novartis logo

Novartis·Phase 4·NCT00414765·26 enrolled

Chronic Graft Versus Host Disease1 trial

Extracorporeal Photopheresis and Low Dose Aldesleukin in Treating Patients With Steroid Refractory Chronic Graft-Versus-Host Disease

Completed·—·Phase 2·NCT03007238·10 enrolled

COVID-191 trial

Survival TRial Using CytoKines in COVID-19 (STRUCK Trial)

Completed·UUniversity of Sao Paulo·Phase 3·NCT04724629·60 enrolled

Intestinal Cancer1 trial

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

Completed·IIntima Bioscience, Inc.·Phase 1/2·NCT04426669·23 enrolled

Induction Therapy1 trial

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Recruiting·CChristian Hinrichs·Phase 1/2·NCT05639972·15 enrolled

Gastrointestinal1 trial

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT06690281

Vaccine1 trial

DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC

Completed·—·Phase 2·NCT00085436·18 enrolled

Clear Cell Renal Carcinoma1 trial

Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma

Completed·OOhio State University Comprehensive Cancer Center·Phase 1·NCT00418496·17 enrolled

Stem Cell Transplantation1 trial

Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer

Completed·CCancer Treatment Centers of America·Phase 2·NCT00003408·40 enrolled

Merkel Cell Carcinoma1 trial

Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma

Terminated·FFred Hutchinson Cancer Center·Phase 1/2·NCT01758458·4 enrolled

Pancreatic Cancer1 trial

BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 1/2·NCT02620865·2 enrolled

Relapsed or Refractory1 trial

Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00871689·2 enrolled

Gastrointestinal Tumors1 trial

CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT02757391·1 enrolled

Infusion1 trial

Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)

Unknown status·SSt. Anna Kinderkrebsforschung·Phase 1/2·NCT01701479·288 enrolled

Liver Cancer1 trial

Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00004248·24 enrolled

Lung Cancer1 trial

KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer

Recruiting·CChristian Hinrichs·Phase 1·NCT05483491·30 enrolled

Brain Tumors1 trial

Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors

Completed·UUniversity of Colorado, Denver·Phase 1·NCT00002572·10 enrolled

Precursor B-Cell Acute Lymphoblastic Leukemia1 trial

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT01700946·80 enrolled

Acute Leukemia1 trial

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia

Completed·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00008190

Metastatic Colorectal Cancer1 trial

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00019591

Metastatic Solid Tumors1 trial

Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019331

Glioma1 trial

Biological Therapy in Treating Patients With Primary or Advanced Glioma

Suspended·WWeill Medical College of Cornell University·Phase 2·NCT00003067

Chronic Myelogenous Leukemia1 trial

Chemotherapy Followed by Peripheral Stem Cell Transplantation And Biological Therapy in Treating Patients With Chronic Myelogenous Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00005948

Hepatitis C1 trial

Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00015652·24 enrolled

Myeloid Leukemia1 trial

Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant

Terminated·FFred Hutchinson Cancer Center·Phase 1/2·NCT00052598·7 enrolled

Head and Neck Cancer1 trial

Microsphere-Delivered Cytokines in Increasing Tumor Response in Lymphocytes From Patients With Head and Neck Cancer

Completed·NNYU Langone Health·N/A·NCT00899821

Cytomegalovirus (CMV)1 trial

A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis

Completed·CChiron Corporation·Phase 1·NCT00002321

Treatment1 trial

CISH Inactivated TILs in the Treatment of NSCLC

Withdrawn·IIntima Bioscience, Inc.·Phase 1/2·NCT05566223

Patients With Advanced Solid Tumors1 trial

Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00005604·25 enrolled

Advanced Solid Tumor1 trial

Immunotherapy for the Treatment of Advanced Solid Tumor

Recruiting·TTongji Hospital·Phase 1/2·NCT03658785·40 enrolled

Chemotherapy1 trial

Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01118091·12 enrolled

Brain Cancer1 trial

Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00014573

Vascular Inflammation1 trial

Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up Study

Recruiting·—··NCT06427694·60 enrolled

Uveal Melanoma1 trial

Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Unknown status·MM.D. Anderson Cancer Center·Phase 1·NCT03068624·34 enrolled

Immune System1 trial

Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00006066·92 enrolled

Myelodysplastic Syndrome1 trial

Interleukin-2 in Treating Patients With Myelodysplastic Syndrome

Completed·UUniversity of Washington·Phase 1·NCT00002746·24 enrolled

Locally Advanced Solid Tumor1 trial

Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1

Completed·JJonsson Comprehensive Cancer Center·Phase 1·NCT02775292·1 enrolled

Advanced Malignancies1 trial

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT01697527·6 enrolled

Ocular Melanoma1 trial

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01814046·24 enrolled

Primary Peritoneal Cancer1 trial

Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent

Withdrawn·BBarbara Ann Karmanos Cancer Institute·Phase 1·NCT02470559

Follicular Lymphoma1 trial

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00020462

Unresectable Cancer1 trial

Inhaled Interleukin-2 in Treating Patients With Metastatic or Unresectable Cancer

Terminated·UUniversity of Southern California·Phase 1·NCT00003009·16 enrolled

Mantle Cell Lymphoma1 trial

Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Completed·NNorthwestern University·Phase 2·NCT00004231

Multiple Myeloma1 trial

Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma

Completed·MMayo Clinic·Phase 2·NCT00616720·15 enrolled

Hematological Malignancies1 trial

Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological Malignancies

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT01630564·2 enrolled

Unspecified1 trial

Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes

Terminated·—·Phase 1·NCT02774291·3 enrolled

Regulatory

FDA Approval Timeline[4]

May 5, 1992

PROLEUKIN

BLA BLA103293

Sources

References

[1]
ClinicalTrials.gov — 321 trial records for Aldesleukin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aldesleukin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Aldesleukin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA103293). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Iovance Biotherapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Interleukin-2 Receptor Agonist[2]
Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: IIovance Biotherapeutics, Inc.

Related News